文献速递流行病学与生物统计医学教育与科研方法

评估凸显罕见遗传病核心结局集开发标准亟需改进

Assessment highlights need for improvement in standards of development of core outcome sets for rare genetic diseases.
PubMed 文献 · J Clin Epidemiol · 2023-07-07

该研究基于COMET数据库,由两名独立评估者依据COS-STAD标准,对针对罕见遗传病(患病率低于1/2000)的核心结局集开发研究进行基线评估,共纳入9项研究、涉及8种不同罕见遗传病,无一项研究满足全部标准,满足标准数范围为6至10项,中位数为7项。作者认为这是首个针对罕见遗传病COS-STAD的评估,凸显在考虑的罕见病数量、方法学(尤其是共识过程)及报告方面亟需改进。

要点

  • 共纳入9项罕见遗传病核心结局集开发研究,涉及8种不同罕见遗传病。
  • 无一项研究满足COS-STAD全部标准,满足标准数范围为6至10项,中位数为7项。
  • 作者认为亟需在考虑的罕见病数量、方法学(尤其共识过程)和报告方面改进。

核心结论

  • 该研究是首个针对罕见遗传病评估COS-STAD的研究,凸显亟需改进:一是考虑的罕见病数量,二是方法学(尤其共识过程),三是COS开发研究的报告。

研究设计与样本

  • 研究纳入关注罕见遗传病核心结局集开发的研究,由两名独立评估者依据COS-STAD标准进行评估。
  • 共纳入9项核心结局集研究,涉及8种不同罕见遗传病。

主要发现

  • 无一项研究满足COS-STAD全部开发标准。
  • 满足标准数范围为6至10项,中位数为7项。

关键数值与推荐

  • 罕见病定义为患病率低于1/2000。
  • COS-STAD为核心结局集开发过程中应考虑的最低推荐标准集。
  • COMET数据库根据最新系统综述收录近400项已发表的核心结局集研究。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A rare disease is classified as such if it affects less than one person in 2,000. The Core Outcome Set STandards for Development (COS-STAD) is a set of standards that represent the minimum recommendations to be considered in the process of core outcome set (COS) development. The aim of this study was to provide a baseline assessment of COS development standards for rare genetic diseases. STUDY DESIGN AND SETTING: Core Outcome Measures in Effectiveness Trials (COMET) database contains nearly 400 published COS studies according to the latest systematic review. Studies focusing on COS development for rare genetic diseases were eligible for inclusion and were assessed by two independent evaluators. RESULTS: Nine COS studies were included in the analysis. Eight different rare genetic diseases were investigated. None of the studies met all the standards for development. The number of standards met ranged from 6 to 10, and the median was 7. CONCLUSION: This study is the first study to assess COS-STAD for rare genetic diseases, and it highlights a great need for improvement. First in terms of numbers of rare diseases considered for COS developments, second in methodology, particularly regarding the consensus process, and third in reporting of the COS development studies.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Ciucă A, Banka S, Newman WG, et al. Assessment highlights need for improvement in standards of development of core outcome sets for rare genetic diseases. J Clin Epidemiol. 2023. PMID: 37423316. doi:10.1016/j.jclinepi.2023.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。